MD1443G2 - Fracţie de copolimer-1, procedeu de obţinere a ei şi compoziţii pe baza acesteia pentru tratamentul sclerozei diseminate - Google Patents

Fracţie de copolimer-1, procedeu de obţinere a ei şi compoziţii pe baza acesteia pentru tratamentul sclerozei diseminate

Info

Publication number
MD1443G2
MD1443G2 MD97-0024A MD970024A MD1443G2 MD 1443 G2 MD1443 G2 MD 1443G2 MD 970024 A MD970024 A MD 970024A MD 1443 G2 MD1443 G2 MD 1443G2
Authority
MD
Moldova
Prior art keywords
copolymer
base
fraction
compositions
preparation
Prior art date
Application number
MD97-0024A
Other languages
English (en)
Russian (ru)
Other versions
MD1443F1 (ro
Inventor
Eliezer Konfino
Michael Sela
Dvora Teitelbaum
Ruth Arnon
Original Assignee
Yeda Research And Development Co., Ltd
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=26939072&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=MD1443(G2) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Application filed by Yeda Research And Development Co., Ltd filed Critical Yeda Research And Development Co., Ltd
Publication of MD1443F1 publication Critical patent/MD1443F1/ro
Publication of MD1443G2 publication Critical patent/MD1443G2/ro

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/74—Synthetic polymeric materials
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • A61K38/1703—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/46—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates
    • C07K14/47—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates from mammals
    • C07K14/4701—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates from mammals not used
    • C07K14/4713—Autoimmune diseases, e.g. Insulin-dependent diabetes mellitus, multiple sclerosis, rheumathoid arthritis, systemic lupus erythematosus; Autoantigens
    • C—CHEMISTRY; METALLURGY
    • C08—ORGANIC MACROMOLECULAR COMPOUNDS; THEIR PREPARATION OR CHEMICAL WORKING-UP; COMPOSITIONS BASED THEREON
    • C08G—MACROMOLECULAR COMPOUNDS OBTAINED OTHERWISE THAN BY REACTIONS ONLY INVOLVING UNSATURATED CARBON-TO-CARBON BONDS
    • C08G69/00—Macromolecular compounds obtained by reactions forming a carboxylic amide link in the main chain of the macromolecule
    • C08G69/02—Polyamides derived from amino-carboxylic acids or from polyamines and polycarboxylic acids
    • C08G69/08—Polyamides derived from amino-carboxylic acids or from polyamines and polycarboxylic acids derived from amino-carboxylic acids
    • C08G69/10—Alpha-amino-carboxylic acids

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Organic Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Animal Behavior & Ethology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Immunology (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Zoology (AREA)
  • Biomedical Technology (AREA)
  • Epidemiology (AREA)
  • Neurology (AREA)
  • Neurosurgery (AREA)
  • Rheumatology (AREA)
  • Rehabilitation Therapy (AREA)
  • Toxicology (AREA)
  • Hematology (AREA)
  • Diabetes (AREA)
  • Biochemistry (AREA)
  • Biophysics (AREA)
  • Genetics & Genomics (AREA)
  • Molecular Biology (AREA)
  • Polymers & Plastics (AREA)
  • Marine Sciences & Fisheries (AREA)
  • Psychiatry (AREA)
  • Hospice & Palliative Care (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Compositions Of Macromolecular Compounds (AREA)
  • Addition Polymer Or Copolymer, Post-Treatments, Or Chemical Modifications (AREA)
  • Polyamides (AREA)

Abstract

Invenţia se referă la fracţii de copolimer-1, ce posedă o toxicitate redusă, care reprezintă un analog polipeptidic sintetic al proteinei de bază a mielinei.Esenţa invenţiei constă în aceea că pentru a micşora toxicitatea se obţin fracţii cu un conţinut redus de specii de copolimer-1 cu o masă moleculară mai mare de 40 kDa. Produsul obţinut poate fi utilizat ca agent terapeutic pentru tratamentul sclerozei diseminate.
MD97-0024A 1994-05-24 1995-05-23 Fracţie de copolimer-1, procedeu de obţinere a ei şi compoziţii pe baza acesteia pentru tratamentul sclerozei diseminate MD1443G2 (ro)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US24803794A 1994-05-24 1994-05-24
US34424894A 1994-11-23 1994-11-23
PCT/US1995/006551 WO1995031990A1 (en) 1994-05-24 1995-05-23 Copolymer-1 improvements in compositions of copolymers

Publications (2)

Publication Number Publication Date
MD1443F1 MD1443F1 (ro) 2000-04-30
MD1443G2 true MD1443G2 (ro) 2000-11-30

Family

ID=26939072

Family Applications (1)

Application Number Title Priority Date Filing Date
MD97-0024A MD1443G2 (ro) 1994-05-24 1995-05-23 Fracţie de copolimer-1, procedeu de obţinere a ei şi compoziţii pe baza acesteia pentru tratamentul sclerozei diseminate

Country Status (31)

Country Link
US (11) US5800808A (ro)
EP (1) EP0762888B1 (ro)
JP (2) JPH10500955A (ro)
KR (1) KR100403750B1 (ro)
CN (2) CN1174753C (ro)
AT (1) ATE212857T1 (ro)
AU (1) AU2602195A (ro)
BR (2) BRPI9507758B1 (ro)
CA (1) CA2191088C (ro)
CZ (1) CZ292247B6 (ro)
DE (2) DE69525340T2 (ro)
DK (1) DK0762888T3 (ro)
EE (1) EE03423B1 (ro)
ES (1) ES2172586T3 (ro)
FI (1) FI120236B (ro)
GE (1) GEP20002205B (ro)
HK (1) HK1008657A1 (ro)
HU (1) HU223473B1 (ro)
IL (2) IL113812A (ro)
LU (1) LU90987I2 (ro)
MD (1) MD1443G2 (ro)
NL (1) NL300096I2 (ro)
NO (1) NO324528B1 (ro)
NZ (1) NZ287335A (ro)
PL (1) PL181026B1 (ro)
PT (1) PT762888E (ro)
SI (1) SI0762888T1 (ro)
SK (1) SK283699B6 (ro)
TJ (1) TJ392B (ro)
UA (1) UA62908C2 (ro)
WO (1) WO1995031990A1 (ro)

Families Citing this family (129)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5858980A (en) * 1990-03-30 1999-01-12 Autoimmune, Inc. Peptide fragments of myelin basic protein
US7090982B2 (en) 1991-10-22 2006-08-15 The Governors Of The University Of Alberta Methods of predicting therapeutic efficacy of treatment of a multiple sclerosis patient
US6252040B1 (en) 1991-10-22 2001-06-26 The Governors Of The University Of Alberta Peptide specificity of anti-myelin basic protein and the administration of myelin basic protein peptides to multiple sclerosis patients
US5800808A (en) 1994-05-24 1998-09-01 Veda Research And Development Co., Ltd. Copolymer-1 improvements in compositions of copolymers
US5858964A (en) * 1995-04-14 1999-01-12 Yeda Research And Development Co. Ltd. Pharmaceutical compositions comprising synthetic peptide copolymer for prevention of GVHD
IL119989A0 (en) * 1997-01-10 1997-04-15 Yeda Res & Dev Pharmaceutical compositions for oral treatment of multiple sclerosis
EP1054880A1 (en) * 1998-02-13 2000-11-29 Autoimmune, Inc. TREATMENT OF MULTIPLE SCLEROSIS USING COP-1 AND Th2-ENHANCING CYTOKINES
WO2000005249A2 (en) 1998-07-23 2000-02-03 The President And Fellows Of Harvard College Synthetic peptides and methods of use for autoimmune disease therapies
EP1098902A4 (en) 1998-07-23 2002-07-24 Yeda Res & Dev TREATMENT OF AUTOIMMUNE DISEASES BY COPOLYMER 1 AND SIMILAR COPOLYMERS AND PEPTIDES
ES2527760T3 (es) * 1998-07-23 2015-01-29 Yeda Research And Development Co., Ltd. Tratamiento de enfermedad de Crohn con copolímero 1 y polipéptidos
ZA200102269B (en) 1998-09-25 2002-03-19 Yeda Res & Dev Copolymer 1 related polypeptides for use as molecular weight markers and for therapeutic use.
US6800287B2 (en) * 1998-09-25 2004-10-05 Yeda Research And Development Co., Ltd. Copolymer 1 related polypeptides for use as molecular weight markers and for therapeutic use
US6514938B1 (en) 1998-09-25 2003-02-04 Yeda Research And Development Co. Ltd. At The Weizmann Institute Of Science Copolymer 1 related polypeptides for use as molecular weight markers and for therapeutic use
WO2000020010A1 (en) * 1998-10-02 2000-04-13 Yeda Research And Development Co., Ltd. Alternate day administration of copolymer 1 for treating autoimmune diseases
US7083777B1 (en) 1999-04-02 2006-08-01 The Brigham And Women's Hospital, Inc. Immunomodulating polymers
ES2243450T3 (es) * 2000-01-20 2005-12-01 Yeda Research And Development Co. Ltd. El uso de copolimero 1 y peptidos y polipeptidos relacionados, y de celulas t tratadas con los mismos, para terapia neuroprotectora.
CA2400374A1 (en) * 2000-02-18 2001-08-23 Adrian Gilbert Oral, nasal and pulmonary dosage formualtions of copolymer 1
US7022663B2 (en) * 2000-02-18 2006-04-04 Yeda Research And Development Co., Ltd. Oral, nasal and pulmonary dosage formulations of copolymer 1
AU7528001A (en) * 2000-06-05 2001-12-17 Teva Pharma The use of glatiramer acetate (copolymer 1) in the treatment of central nervous system disorders
US20020077278A1 (en) * 2000-06-05 2002-06-20 Yong V. Wee Use of glatiramer acetate (copolymer 1) in the treatment of central nervous system disorders
US20020037848A1 (en) * 2000-06-07 2002-03-28 Michal Eisenbach-Schwartz Use of copolymer 1 and related peptides and polypeptides and T cells treated therewith for neuroprotective therapy
WO2002076503A1 (en) * 2000-06-20 2002-10-03 Mayo Foundation For Medical Education And Research Treatment of central nervous system diseases by antibodies against glatiramer acetate
WO2001097785A2 (en) * 2000-06-20 2001-12-27 Caprion Pharmaceuticals Inc. Basic copolymers for the treatment of prion-related-disease
IL137460A0 (en) * 2000-07-24 2001-07-24 Yeda Res & Dev Identifying antigen clusters for monitoring a global state of an immune system
US20040037828A1 (en) 2002-07-09 2004-02-26 Bar-Ilan University Methods and pharmaceutical compositions for healing wounds
SV2003000753A (es) 2000-12-05 2003-06-16 Brigham & Womens Hospital Uso de polisacaridos zwitterionicos para la especifica modulacion del progreso inmunologico
GB2369896A (en) 2000-12-06 2002-06-12 Marconi Comm Ltd Tunable optical filter actuator
KR100442122B1 (ko) * 2001-07-31 2004-07-30 한국전기연구원 영구 자석을 이용한 브러시리스 발전기
US7429374B2 (en) * 2001-12-04 2008-09-30 Teva Pharmaceutical Industries, Ltd. Process for the measurement of the potency of glatiramer acetate
EP1429800B1 (en) * 2001-12-06 2009-02-11 Yeda Research And Development Co., Ltd. Vaccine and use thereof for treatment of amyotrophic lateral sclerosis
US20060057107A1 (en) * 2001-12-21 2006-03-16 Shaked Ze Ev Combination treatment for multiple sclerosis
ATE548045T1 (de) 2003-01-07 2012-03-15 Yeda Res & Dev Vakzine in augentropfenform enthaltend copolymer 1 für die therapeutische immunisierung
MXPA05007711A (es) * 2003-01-21 2005-09-30 Yeda Res & Dev Copolimero 1 para el tratamiento de enfermedades inflamatorias del intestino.
EP1603530A1 (en) * 2003-03-04 2005-12-14 Teva Pharmaceutical Industries Limited Combination therapy with glatiramer acetate and alphacalcidol for the treatment of multiple sclerosis
US20040219160A1 (en) 2003-03-31 2004-11-04 The Brigham And Women's Hospital, Inc. Zwitterionic immunomodulators for the treatment of asthma and allergy
NZ546379A (en) * 2003-10-31 2010-04-30 Teva Pharma Nanoparticles for drug delivery
EP1684797A1 (en) 2003-11-12 2006-08-02 Yeda Research and Development Co. Ltd. Vaccine and method for treatment of neurodegenerative diseases
JP4808631B2 (ja) 2003-12-09 2011-11-02 イエダ リサーチ アンド デベロップメント カンパニー リミテッド 精神医学的障害の治療用のコポリマー１を含む方法及びワクチン
CA2556152A1 (en) * 2004-02-02 2005-08-18 Mixture Sciences, Inc. Peptide mixtures with immunomodulatory activity
CA2558655A1 (en) * 2004-03-01 2005-09-15 Kai W. Wucherpfennig Methods and compositions for treatment of autoimmune diseases
CA2558380A1 (en) * 2004-03-03 2005-09-15 Teva Pharmaceutical Industries, Ltd. Combination therapy with glatiramer acetate and riluzole
US20050260770A1 (en) * 2004-04-01 2005-11-24 Cohen Irun R Antigen array and diagnostic uses thereof
US7655221B2 (en) * 2004-05-07 2010-02-02 Peptimmune, Inc. Methods of treating disease with random copolymers
WO2005120542A2 (en) 2004-05-07 2005-12-22 Peptimmune, Inc. Methods of treating disease with random copolymers
US20060194725A1 (en) * 2004-05-07 2006-08-31 James Rasmussen Methods of treating disease with random copolymers
SG186686A1 (en) 2004-06-25 2013-01-30 Id Biomedical Corp Quebec Compositions and methods for treating neurological disorders
NZ554018A (en) 2004-09-09 2009-06-26 Teva Pharma Process for preparation of trifluoroacetyl glatiramer acetate using purified hydrobromic acid
WO2006029411A2 (en) * 2004-09-09 2006-03-16 Yeda Research And Development Co. Ltd. Mixtures of polypeptides, compositions containing and processes for preparing same, and uses thereof
AR052321A1 (es) * 2004-10-29 2007-03-14 Sandoz Ag Procesos para la preparacion de un polipeptido
US8324641B2 (en) * 2007-06-29 2012-12-04 Ledengin, Inc. Matrix material including an embedded dispersion of beads for a light-emitting device
US20090191173A1 (en) * 2004-11-29 2009-07-30 Michal Eisenbach-Schwartz Induction Of Neurogenesis And Stem Cell Therapy In Combination With Copolymer 1
US20060172942A1 (en) * 2005-02-02 2006-08-03 Teva Pharmaceutical Industries, Ltd. Process for producing polypeptide mixtures using hydrogenolysis
US20100167983A1 (en) * 2007-10-22 2010-07-01 Teva Pharmaceutical Industries, Ltd. Combination therapy with glatiramer acetate and rasagiline for the treatment of multiple sclerosis
SI1848415T1 (sl) * 2005-02-17 2013-08-30 Teva Pharmaceutical Industries Ltd. Kombinacijska terapija z glatiramer acetatom in razagilinom za zdravljenje muliple skleroze
EP1891233A4 (en) * 2005-04-25 2010-03-24 Yeda Res & Dev MARKERS ASSOCIATED WITH THERAPY EFFECTIVENESS OF GLATIRAMERATE ACETATE
WO2007081975A2 (en) * 2006-01-11 2007-07-19 Teva Pharmaceutical Industries, Ltd. Method of treating multiple sclerosis
US8206726B2 (en) 2006-02-06 2012-06-26 The Brigham And Women's Hospital, Inc. Zwitterionic polysaccharides for promotion of immune system maturation and health
WO2007120834A2 (en) 2006-04-13 2007-10-25 Peptimmune, Inc. Methods for designing and synthesizing directed sequence polymer compositions via the directed expansion of epitope permeability
EP2013628B1 (en) 2006-04-28 2016-01-06 Momenta Pharmaceuticals, Inc. Methods of evaluating peptide mixtures
KR100831796B1 (ko) * 2006-05-29 2008-05-28 엘지전자 주식회사 타임 쉬프트 기능을 내장한 영상표시기기 및 그 재생 방법
US9089509B2 (en) 2006-06-28 2015-07-28 Yeda Research And Development Co., Ltd. Method of treatment of age-related macular degeneration
AU2007269140A1 (en) * 2006-07-05 2008-01-10 Momenta Pharmaceuticals, Inc. Improved process for the preparation of copolymer-1
EP2381254B2 (en) 2007-06-21 2017-07-19 Momenta Pharmaceuticals, Inc. Copolymer assay
US20090029766A1 (en) * 2007-07-26 2009-01-29 Lutnick Howard W Amusement gaming access and authorization point
WO2009016643A1 (en) * 2007-07-31 2009-02-05 Natco Pharma Limited Process for the preparation glatiramer acetate (copolymer-1)
EP2586460A1 (en) 2007-10-16 2013-05-01 Peptimmune, Inc. Method for designing and preparing vaccines comprising directed sequence polymer composition via the directed expansion of epitopes
JP2011503104A (ja) 2007-11-09 2011-01-27 カリフォルニア インスティテュート オブ テクノロジー 免疫調節化合物ならびに関連組成物および方法
EA201070656A1 (ru) * 2007-11-28 2010-12-30 Тева Фармасьютикал Индастриз, Лтд. Способ задержки начала проявления клинически определенного рассеянного склероза
WO2009129018A1 (en) 2008-04-16 2009-10-22 Momenta Pharmaceuticals, Inc. Analysis of amino acid copolymer compositions
WO2010017292A1 (en) * 2008-08-07 2010-02-11 Scinopharm Taiwan, Ltd. Synthesis of glatiramer acetate
PL2307448T3 (pl) * 2008-08-07 2015-10-30 Sigma Aldrich Co Llc Wytwarzanie polilizyny i poliornityny o małym ciężarze cząsteczkowym z wysoką wydajnością
US9617313B2 (en) 2008-12-24 2017-04-11 Synthon Bv Process for purifying a polymer mixture
WO2010115175A1 (en) * 2009-04-03 2010-10-07 Momenta Pharmaceticals, Inc. Control of copolymer compositions
AU2009347384B2 (en) * 2009-06-04 2014-10-23 Council Of Scientific & Industrial Research A process for the preparation of copolymer - 1 (Cop-I), composed of L-alanine, L-lysine, L-glutamic acid and L-tyrosine-drug for the treatment of multiple sclerosis
DK2275086T3 (da) * 2009-07-15 2012-07-09 Teva Pharma Reduceret volumenformulering af glatirameracetat og fremgangsmåder til administration heraf
US8920373B2 (en) 2009-07-15 2014-12-30 Teva Pharmaceutical Industries, Ltd. Reduced volume formulation of glatiramer acetate and methods of administration
US8691790B2 (en) * 2009-07-27 2014-04-08 James Layne Boucher Therapy of neurological inflammatory diseases with (5'-deoxy-5'-adenosyl) cobamamide, recombinant human growth hormone, interleukins IL-1, IL-6, IL-11, epidermal growth factor, and physiotherapy
RS52885B (en) 2009-08-20 2014-02-28 Yeda Research And Development Co. Ltd. LOW-FREQUENCY GLATIRAMER ACETATOM THERAPY
JP5916622B2 (ja) 2010-01-04 2016-05-11 マピ ファーマ リミテッド グラチラマーまたはその薬理学的に許容される塩を含むデポーシステム
USRE49251E1 (en) 2010-01-04 2022-10-18 Mapi Pharma Ltd. Depot systems comprising glatiramer or pharmacologically acceptable salt thereof
US8377885B2 (en) 2010-01-04 2013-02-19 Mapi Pharma Ltd. Depot systems comprising glatiramer or pharmacologically acceptable salt thereof
EP2523668A1 (en) 2010-01-13 2012-11-21 Ramot at Tel-Aviv University Ltd Treatment of multiple sclerosis
US8759302B2 (en) 2010-03-16 2014-06-24 Teva Pharmaceutical Industries, Ltd. Methods of treating a subject afflicted with an autoimmune disease using predictive biomarkers of clinical response to glatiramer acetate therapy in multiple sclerosis
EP2555753B1 (en) 2010-04-07 2018-08-01 California Institute of Technology Vehicle for delivering a compound to a mucous membrane and related compositions, methods and systems
AU2011248663A1 (en) * 2010-04-27 2012-11-08 Dr. Reddy's Laboratories Ltd. Preparation of polypeptides and salts thereof
JP2013530949A (ja) 2010-05-20 2013-08-01 エル ラウンド ジューン 抗原特異的Ｔｒｅｇ並びに関連する組成物、方法及びシステム
RU2013108828A (ru) * 2010-07-29 2014-09-10 Др. Редди'С Лабораторис Лтд. Маркеры молекулярной массы глатирамера ацетата
MX347871B (es) 2010-10-11 2017-05-16 Teva Pharmaceutical Ind Ltd * Biomarcadores de citoquina como marcadores predictivos de respuesta clínica para acetato de glatirámero.
EP2675824B1 (en) 2011-02-14 2017-09-27 USV Private Limited Copolymer-1, process for preparation and analytical methods thereof
ES2601892T3 (es) 2011-04-21 2017-02-16 Mapi Pharma Limited Pentapolímero aleatorio para el tratamiento de enfermedades autoinmunes
US20140348861A1 (en) 2011-05-05 2014-11-27 National Institute Of Immunology Synthetic peptides and random copolymers for the treatment of autoimmune disorders
WO2013009885A2 (en) 2011-07-11 2013-01-17 Momenta Pharmaceuticals, Inc. Evaluation of copolymer diethylamide
WO2013009864A1 (en) 2011-07-11 2013-01-17 Momenta Pharmaceuticals, Inc. Structure assessment of heterogeneous polypeptide mixtures
JP6273200B2 (ja) 2011-07-12 2018-01-31 ザ・ブリガーム・アンド・ウーメンズ・ホスピタル・インコーポレーテッド 脂質含有ｐｓａ組成物、その単離の方法および使用の方法
US8575198B1 (en) 2011-09-07 2013-11-05 Momenta Pharmaceuticals, Inc. In-process control for the manufacture of glatiramer acetate
EA201490749A1 (ru) 2011-10-10 2014-09-30 Тева Фармасьютикал Индастриз Лтд. Однонуклеотидные полиморфизмы, полезные для прогнозирования клинической реакции на глатирамера ацетат
WO2013139728A1 (en) 2012-03-19 2013-09-26 Synthon Bv Glatiramer acetate human monocyte cell-based potency assay
EP2642290A1 (en) 2012-03-19 2013-09-25 Synthon BV Glatiramer acetate human monocytic cell line-based potency assay
US20140045740A1 (en) * 2012-08-13 2014-02-13 Momenta Pharmaceuticals, Inc. Analysis of glatiramer acetate
WO2014058976A2 (en) 2012-10-10 2014-04-17 Teva Pharmaceutical Industries Ltd. Biomarkers predictive for clinical response for glatiramer acetate
WO2014060942A2 (en) * 2012-10-20 2014-04-24 Mahesh Kandula Compositions and methods of for the treatment of multiple sclerosis and neurodegenerative diseases
WO2014128079A1 (en) 2013-02-19 2014-08-28 Synthon B.V. Glatiramer acetate multidose formulation
DK2774639T3 (en) 2013-03-08 2015-01-12 Teva Pharma Reusable injection device for a syringe
PT2774640E (pt) 2013-03-08 2015-02-09 Teva Pharma Dispositivo injector reutilizável para seringa
WO2014159685A2 (en) 2013-03-14 2014-10-02 Mylan Inc. Glatiramer acetate response biomarker mrna potency assay
WO2014173463A1 (en) 2013-04-26 2014-10-30 Synthon Bv Glatiramer acetate human monocytic cell line-based potency assay
JP2016521284A (ja) 2013-05-10 2016-07-21 カリフォルニア インスティチュート オブ テクノロジー 大腸ガンのプロバイオティクスによる防止および処置
CN103265624B (zh) * 2013-05-27 2015-04-22 成都圣诺生物制药有限公司 格拉替雷的制备方法
CN104371012A (zh) * 2013-08-12 2015-02-25 深圳翰宇药业股份有限公司 一种合成醋酸格拉替雷的方法
UY35790A (es) 2013-10-21 2015-05-29 Teva Pharma Marcadores genéticos que predicen la respuesta al acetato de glatiramer
CA2928084A1 (en) 2013-10-24 2015-04-30 Mylan Inc. Human t cell line assay for evaluating the immunologic identity of glatiramer acetate preparations
JP2017503169A (ja) 2013-12-31 2017-01-26 イエダ・リサーチ・アンド・デベロツプメント・カンパニー・リミテツド オリゴヌクレオチド抗原を使用する全身性エリテマトーデスの診断
US10144778B2 (en) 2014-03-12 2018-12-04 Yeda Research And Development Co. Ltd Reducing systemic regulatory T cell levels or activity for treatment of disease and injury of the CNS
CN104844697B (zh) 2014-09-26 2018-10-23 深圳翰宇药业股份有限公司 醋酸格拉替雷的制备方法
US9155775B1 (en) 2015-01-28 2015-10-13 Teva Pharmaceutical Industries, Ltd. Process for manufacturing glatiramer acetate product
US11047855B2 (en) 2015-03-01 2021-06-29 Immunarray Ltd. Diagnosis of systemic lupus erythematosus using protein, peptide and oligonucleotide antigens
WO2016201342A1 (en) 2015-06-10 2016-12-15 California Institute Of Technology Sepsis treatment and related compositions methods and systems
JP6918365B2 (ja) 2015-08-19 2021-08-11 プレジデント アンド フェローズ オブ ハーバード カレッジ 脂質化ｐｓａ組成物および方法
EP3147667B1 (en) 2015-09-24 2019-06-12 CHEMI S.p.A. Analysis of the molecular weight distribution of complex polypeptide mixtures
ES2707500T3 (es) 2015-11-23 2019-04-03 Chemi Spa Análisis mediante RP-HPLC de mezclas de polipéptidos complejos
CN107522774B (zh) * 2016-06-22 2021-07-02 深圳翰宇药业股份有限公司 一种醋酸格拉替雷制备过程中哌啶残留量的实时控制方法
US20210220428A1 (en) 2016-06-30 2021-07-22 Stem Cell Medicine Ltd. Treatment of inflammatory bowel disease with long acting glatiramer and adipose-derived stem cells
US11491181B2 (en) 2016-07-15 2022-11-08 President And Fellows Of Harvard College Glycolipid compositions and methods of use
BR112019003131A2 (pt) 2016-08-28 2019-05-21 Mapi Pharma Ltd. processo para preparar micropartículas contendo acetato de glatirâmero
JP7193448B2 (ja) 2016-08-31 2022-12-20 マピ ファーマ リミテッド 酢酸グラチラマーを含むデポシステム
MX2019010174A (es) 2017-03-26 2019-10-15 Mapi Pharma Ltd Sistemas de deposito de glatiramer para el tratamiento de formas progresivas de esclerosis multiple.
AU2017414803A1 (en) 2017-05-15 2019-12-05 Mapi Pharma Ltd. Treatment of multiple sclerosis with long acting glatiramer and adipose-derived stem cells
WO2018211498A1 (en) 2017-05-15 2018-11-22 Stem Cell Medicine Ltd. Treatment of multiple sclerosis with adipose-derived stem cells
WO2019175869A1 (en) 2018-03-12 2019-09-19 Yeda Research And Development Co. Ltd Treatment of a heart disease

Citations (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US3849550A (en) * 1971-04-21 1974-11-19 Yeda Res & Dev Therapeutic copolymer
EP0383620A2 (en) * 1989-02-17 1990-08-22 Repligen Corporation Process for making genes encoding random polymers of amino acids

Family Cites Families (18)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4444760A (en) * 1983-06-17 1984-04-24 Merck & Co., Inc. Purification and characterization of a protein fibroblast growth factor
JPS6053535A (ja) 1983-09-02 1985-03-27 Nitto Boseki Co Ltd 規則性ポリアミノ酸樹脂の製造方法
SU1182051A1 (ru) 1984-04-28 1985-09-30 Таджикский государственный университет им.В.И.Ленина Политрипептиды,обладающие энантовой селективностью в реакци х гидролиза @ -нитрофениловых эфиров карбобензокси - @ - и @ -аланина
ATE73338T1 (de) 1985-06-18 1992-03-15 Univ Emory Biologisch wirksame kopolymere.
DD257174A3 (de) 1985-12-20 1988-06-08 Ve Forschungszentrum Biotechno Verfahren zur herstellung der peptide z-ala-ala-lon-p-nitranilid oder z-asp-phe-ome mit metalloprotease
SU1469826A1 (ru) 1986-05-30 1995-11-20 Институт Высокомолекулярных Соединений Ан Ссср Сополимер l-лизина с l-глутаминовой кислотой, содержащий дофаминовые боковые группы, обладающий пролонгированной гипотензивной активностью и компенсаторным эффектом при геморрагическом шоке, и способ его получения
US4828706A (en) * 1988-03-07 1989-05-09 Spectrum Medical Industries Process for performing a dialysis operation
US4908404A (en) * 1988-08-22 1990-03-13 Biopolymers, Inc. Synthetic amino acid-and/or peptide-containing graft copolymers
DE8900366U1 (de) * 1989-01-13 1989-08-03 Indag Gesellschaft für Industriebedarf mbH, 69214 Eppelheim Folienbeutel
SU1690368A1 (ru) 1989-07-20 1995-08-20 Институт Высокомолекулярных Соединений Ан Ссср Статистические сополимеры в качестве низкотоксичных веществ, обладающих пролонгированным гипотензивным действием, и способ их получения
DE3930733A1 (de) 1989-09-14 1991-03-28 Roehm Gmbh Verfahren zur herstellung eines komplexierten arzneimittels
JP2653255B2 (ja) * 1990-02-13 1997-09-17 武田薬品工業株式会社 長期徐放型マイクロカプセル
JP3345816B2 (ja) * 1991-11-12 2002-11-18 イー・アイ・デユポン・ドウ・ヌムール・アンド・カンパニー コラーゲン様ポリペプチド類
US5800808A (en) * 1994-05-24 1998-09-01 Veda Research And Development Co., Ltd. Copolymer-1 improvements in compositions of copolymers
US6214791B1 (en) * 1997-01-10 2001-04-10 Yeda Research And Development Co. Ltd. Treatment of multiple sclerosis through ingestion or inhalation of copolymer-1
JP2001524011A (ja) 1997-05-06 2001-11-27 クワンタ・ビジョン 組織分析装置
ES2243450T3 (es) * 2000-01-20 2005-12-01 Yeda Research And Development Co. Ltd. El uso de copolimero 1 y peptidos y polipeptidos relacionados, y de celulas t tratadas con los mismos, para terapia neuroprotectora.
US6936539B2 (en) * 2003-09-24 2005-08-30 Micron Technology, Inc. Antireflective coating for use during the manufacture of a semiconductor device

Patent Citations (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US3849550A (en) * 1971-04-21 1974-11-19 Yeda Res & Dev Therapeutic copolymer
EP0383620A2 (en) * 1989-02-17 1990-08-22 Repligen Corporation Process for making genes encoding random polymers of amino acids

Also Published As

Publication number Publication date
PT762888E (pt) 2002-07-31
DE10299030I1 (de) 2003-01-23
FI120236B (fi) 2009-08-14
US6342476B1 (en) 2002-01-29
US6362161B1 (en) 2002-03-26
US7625861B2 (en) 2009-12-01
PL181026B1 (pl) 2001-05-31
HK1008657A1 (en) 1999-05-14
AU2602195A (en) 1995-12-18
WO1995031990A1 (en) 1995-11-30
FI964600A0 (fi) 1996-11-15
NO964976D0 (no) 1996-11-22
US6939539B2 (en) 2005-09-06
HU9603243D0 (en) 1997-01-28
US20120077754A1 (en) 2012-03-29
CZ341096A3 (en) 1997-06-11
US5800808A (en) 1998-09-01
US20030064914A1 (en) 2003-04-03
ES2172586T3 (es) 2002-10-01
NO324528B1 (no) 2007-11-12
EP0762888A1 (en) 1997-03-19
CN1174753C (zh) 2004-11-10
HUT75672A (en) 1997-05-28
CZ292247B6 (cs) 2003-08-13
NL300096I2 (nl) 2003-02-03
KR100403750B1 (ko) 2006-02-13
CA2191088A1 (en) 1995-11-30
KR970703154A (ko) 1997-07-03
FI964600A (fi) 1996-12-05
IL113812A (en) 2000-06-29
LU90987I2 (fr) 2003-02-25
IL133890A0 (en) 2001-04-30
JP3715600B2 (ja) 2005-11-09
EP0762888B1 (en) 2002-02-06
JPH10500955A (ja) 1998-01-27
BRPI9507758B1 (pt) 2021-03-16
US8367605B2 (en) 2013-02-05
DE69525340D1 (de) 2002-03-21
CN1310673C (zh) 2007-04-18
US6620847B2 (en) 2003-09-16
NZ287335A (en) 1999-02-25
SI0762888T1 (en) 2002-08-31
SK149396A3 (en) 1997-08-06
SK283699B6 (sk) 2003-12-02
BR9507758A (pt) 1997-09-23
IL113812A0 (en) 1995-08-31
MD1443F1 (ro) 2000-04-30
DK0762888T3 (da) 2002-05-27
CN1626238A (zh) 2005-06-15
CN1152874A (zh) 1997-06-25
PL317331A1 (en) 1997-04-01
US20050171286A1 (en) 2005-08-04
CA2191088C (en) 2004-09-28
GEP20002205B (en) 2000-08-25
JP2003105000A (ja) 2003-04-09
HU223473B1 (hu) 2004-07-28
DE69525340T2 (de) 2002-09-19
EE03423B1 (et) 2001-06-15
US5981589A (en) 1999-11-09
ATE212857T1 (de) 2002-02-15
UA62908C2 (uk) 2004-01-15
NL300096I1 (nl) 2002-10-01
TJ392B (en) 2004-10-13
EP0762888A4 (ro) 1997-04-16
NO964976L (no) 1997-01-23
US6048898A (en) 2000-04-11
EE9600170A (et) 1997-06-16
US20040106554A1 (en) 2004-06-03
US7199098B2 (en) 2007-04-03
US20070117757A1 (en) 2007-05-24
US6054430A (en) 2000-04-25

Similar Documents

Publication Publication Date Title
MD1443G2 (ro) Fracţie de copolimer-1, procedeu de obţinere a ei şi compoziţii pe baza acesteia pentru tratamentul sclerozei diseminate
EP1440980A3 (en) Peptide analogs of human myelin basic protein
ES2174855T3 (es) Metodos diagnosticos y composiciones farmaceuticas que se basan en proteinas notch y acidos nucleicos.
EP0378641A4 (en) Novel antimicrobial peptide, compositions containing same and uses thereof
AU6020099A (en) Methods for treatment of multiple sclerosis using peptide analogs of human myelin basic protein
EP0131789A3 (en) Composition comprising purified human tumour necrosis factor in conjunction with human interferon and its use
WO1996028470A3 (en) Peptide analogues of human myelin basic protein useful in treating multiple sclerosis
EP0422125A4 (en) Platelet blocking peptides
WO1995016430A3 (de) Kosmetische und/oder pharmazeutische zubereitungen
CA2131565A1 (en) Organopolysiloxanes Containing Hydrophilic Groups
CA2139652A1 (en) Thrombin-inhibitors
CA2047802A1 (en) Pharmaceutical compositions
DE59406722D1 (de) Verwendung boviner Kolostralmilch zur Herstellung eines Arzneimittels für die Behandlung von Leberfunktionsstörungen
CA2139353A1 (en) Pharmaceutical composition containing il-6, their uses for the treatment of consumptive thrombo-hemorrhagic disorder
NZ228208A (en) Eglin compounds (hurudin) and protease inhibitor pharmaceutical compositions
BG101846A (en) HUMAN DNase I VARIANTS
DK0970121T3 (da) Peptidfragmenter af myelin-basisk-protein, deres farmaceutiske sammensætninger og deres anvendelse i behandling af multipel sklerose
CA2153071A1 (en) Derivatized calcitonins
MY113485A (en) Carbon blacks
BG101847A (en) Human dnase i variants
GEP19980954B (en) Ointment “Hypoaskane”

Legal Events

Date Code Title Description
MK4A Patent for invention expired